About US
Contact us
-
Allergan again in eye of the legal storm for foiling competition to RestasisAllergan is again being accused of using unfair tactics to dodge competition for its eye drug Restasis as Shire takes to the courts to try to defeat exclusive contracts it says have kept its competing2017/9/18
-
Does Pfizer really want Bristol-Myers? Likely, says one analyst. What's it waiting for?Investors have had a pointed question for Credit Suisse analysts lately: Is Pfizer buying Bristol-Myers Squibb a question of when, not if? The way analyst Vamil Divan sees it, maybeso. “We remain o2017/9/18
-
AstraZeneca, Tesaro and Clovis need to slash the cost of PARP meds, watchdog saysOvarian cancer patients who respondto chemo have some new treatments designed to keep their disease at bay. But a cost-effectiveness watchdog isn’t convinced those meds are worth their price in that s2017/9/15
-
Cher takes on Patrick Soon-Shiong in shareholder suitFor a second time, billionaire Patrick Soon-Shiong has been sued for allegedly pulling a fast one in his takeover of biotech Altor, but this time it is celebrity singer Cher making the accusations.2017/9/15
-
Generic industry's initial effort to halt Maryland price law rebuffed by judgeTaking a tough stance against Maryland's new pricing regulations, the generic drug industry sought an injunction, hoping to stop the law in its tracks. But the industry's efforts for relief have com2017/9/14
-
Takeda is expanding its EU presence while AstraZeneca talks of pulling production from U.K.While other companies fret about the impact of Brexit, Japan's Takeda will make another investment in its production operations in the European Union. The company will invest up to €100 million in2017/9/14
-
Teva makes good on asset-sale vows with $1.1B contraceptive saleMonday was quite the day for Teva. In addition to naming new CEO Kåre Schultz, the company unveiled the first of the asset sales it’s promised to help pay down debt. Late in the day, the embatt2017/9/13
-
Allergan, author of the 'social contract,' stirs up hornet's nest with controversial IP dealSeeking to shield its blockbuster eye drug against a second round of patent attacks, Allergan has transferred key Restasis intellectual propertyto the Saint Regis Mohawk Tribe.With the unusual move, t2017/9/13
-
Teva finally nabs a CEO, and it's Lundbeck helmsman—and Novo ex—Kåre SchultzAfter seven long months of searching, Teva finally has its new CEO—and as the company hinted it would, it’s poached him from another drugmaker. Lundbeck head honchoKåre Schultz, a longtime Novo2017/9/12
-
ESMO: Merck's Keytruda extends survival edge on its bladder cancer rivalsMADRID, Spain—Right now, Merck’s Keytruda is the only PD-1/PD-L1 med with data to show it can improve overall survival in the second-line bladder cancer setting. And it keeps piling it on. Over the w2017/9/12